Dr Scott Marshall
Scott graduated from Edinburgh University in 1996 with degrees in Medicine and Immunology. He trained in medicine and Haematology in London and the NorthEast. His PhD in Immunology and Transplantation was awarded by Newcastle University. He is a Consultant Haematologist at South Tyneside and Sunderland NHS Trust appointed in 2008 and leads Haematology and Laboratory services across the South of Tyne Hospitals. His practice includes Malignant Haematology and non-malignant Haematology with delivery of intensive treatments up to the level of leukaemia induction and autologous stem cell transplant. He has a special interest in CLL and Teenage & Young adults with cancer. He delivers non-malignant paediatric Haematology services and support to the Paediatric teams in the South of Tyne.
Scott is an active clinical researcher and is lead of a research team that he has built and developed since his appointment at Sunderland. He is a member of the UK NCRI CLL Clinical Trials group which guides UK trials in chronic lymphocytic leukaemia and has delivered many national and international trials including industry sponsored trials. Scott has become a point of contact for industry sponsored pharmaceutical trials in the North East bringing novel treatments and strategies for the benefit of NE patients.
Scott was clinical Director of Medical Specialities at STSFT from 2013 to 2019 giving him much experience for management, project delivery, implementation of novel ways of working and bringing about change. He was appointed as regional lead for Teenage and Young Adults with Cancer in 2022 to build and enhance regional services. He is a consultant appraiser, Case investigator for MHPS and has been an invited clinical expert for NICE for several technology and medicine appraisals.
Laboratory medicine has been transformed by technology, mechanisation and robotics allowing upscale of tests available and throughput. Further developments with artificial intelligence, digital integration and apps that allow patient involvement in healthcare promise transformation of clinical medicine and pathology. Scott is supporting this conference because he recognises the importance of harnessing modern and emerging technology which is likely to be the cornerstone of future healthcare delivery.